AzTrials
AzTrials

Muscle RelaxationPhase 4TIVANCT01930747

Effect of Deep Neuromuscular Block (NMB), Inhalation or TIVA on Pneumoperitoneum.

A Phase 4 study testing rocuronium, Sevoflurane and remifentanyl in people with Muscle Relaxation, run by AZ Sint-Jan AV at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study is to compare the value of deep neuromuscular block (NMB) (using rocuronium) in laparoscopy versus high dose opioids (using remifentanil) or 1 minimum alveolar concentration (MAC) inhalation (using sevoflurane) for the surgeon. Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Muscle Relaxation
What is being tested?
rocuronium, Sevoflurane and remifentanyl
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteBelgium
Study dates
Apr 2013to Apr 2016
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1. Laparoscopic bariatric surgery in a patient older than 18 years of age without previous laparotomy. Examples of laparoscopic bariatric procedures are gastric band, sleeve gastrectomy, gastric bypass, gastric bypass after lap band, and revision of a gastric bypass

Who cannot join

  • Allergies or contraindications to the use of one or more of the following drugs: propofol, rocuronium, sugammadex, remifentanyl, or sevoflurane
  • History of a laparotomy
  • Emergency laparoscopy

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • Azsintjan

    Bruges, 8000

Other trials in Belgium

About this study

Official title: Impact of Deep Neuromuscular Block Versus Inhalation and Total Intravenous Anesthesia (TIVA) on Laparoscopic Surgical Workspace Defined as Insufflated Pneumoperitoneum Volume.

The objective of this study is to compare the value of deep neuromuscular block (NMB) (using rocuronium) in laparoscopy versus high dose opioids (using remifentanil) or 1 minimum alveolar concentration (MAC) inhalation (using sevoflurane) for the surgeon.

The study hypothesis is that laparoscopic workspace is larger when using rocuronium versus opioids or inhalation. Laparoscopic workspace is measured as the abdominal compliance and the pressure at volume zero (PV0) using the abdominal pressure volume relation. Three points allow to calculate the abdominal compliance and the pressure at zero volume (PV0).

Read the detailed description

Background and rationale

The value of administering a deep neuromuscular block (NMB) to reach a post-tetanic count (PTC) of < 4 during laparoscopy is not clear. Some anesthesiologists claim that certain laparoscopic procedures do not need NMB at all and that surgeons cannot objectivize the existence of insufficient workspace and the effect of NMB. They assume that deep anesthesia with remifentanyl improves also the workspace. This assumption may be based on the fact that deep anesthesia prevents spontaneous active muscle contractions. However, preventing an active contraction through deep anesthesia is different from blocking the "active tonus" with a NMB.

Due to the difficulties in evaluating the surgical access, surgical workspace (1) should be measured as the inflated carbon dioxide (CO2) volume for a given intra-abdominal pressure during pneumoperitoneum. Abdominal compliance (C or its reciprocal the elastance: E) and the pressure at zero volume (PV0) are calculated by measuring three or more pressure volume points to construct the abdominal pressure volume relation.

The objective of this study is to compare the value of deep NMB (using rocuronium) in laparoscopy versus high dose opioids (using remifentanil) or 1 Minimum alveolar concentration (MAC) inhalation (using sevoflurane) for the surgeon.

Objectives

  1. Primary Efficacy Objective: To compare the impact of the following agents on the reduction in active muscle tonus during laparoscopy (time frame: during surgery beig maximum 90 minutes) : remifentanyl > 0.50 µg/kg/min; sevoflurane > 1 MAC and deep neuromuscular block (rocuronium given with PTC < 4).
  2. Primary Safety Objective: To compare the adverse events ( time frame: during hospitalisation maximum 3 days after surgery) among the patient groups who receive the different agents listed above in the "primary efficacy objective,"

Hypothesis

  1. High dose remifentanyl does not increase laparoscopic surgical workspace compared to deep NMB (PTC < 4).
  2. 1 MAC inhalation with sevoflurane does not increase laparoscopic surgical workspace compared to deep NMB ( PTC < 4)
  3. Surgeons will encounter more workspace problems when no NMB is used.

Study design

Open randomized blinded clinical trial including:

  1. Laparoscopic bariatric surgery in a patient older than 18 years of age without previous laparotomy. Examples of laparoscopic bariatric procedures are gastric band, sleeve gastrectomy, gastric bypass, gastric bypass after lap band, and revision of a gastric bypass. and excluding:
  2. Allergies or contraindications to the use of one or more of the following drugs: propofol, rocuronium, sugammadex, remifentanyl, or sevoflurane.
  3. History of a laparotomy.
  4. Emergency laparoscopy.

Methods:

Written informed consent will be obtained. The following patient characteristics will be noted: body weight, length, body mass index, age, sex, previous laparoscopic surgery, and gravidity for woman.

Anesthesia will be induced in all patients with Propofol 3 mg/kg ideal body weight (IBW), Ketamine 0,25 mg/kg IBW, Dexmedetomidine 1 ug/kg IBW loading dose, Lidocaine 1,5 mg/kg IBW and Succinylcholine 1 mg/kg total body weight (TBW).

Three Syringes with drugs (I II III) used in all patients (no investigation drugs):

I: Ketamine 50 mg (1cc); Lidocaine 300 mg (2% 15 cc), Dexmedetomidine 200 ug (1cc), 3 cc NaCl 0,9% in 20 cc syringe.

II: Propofol (10 mg/ml) not diluted in 50 cc syringe. III: Succinylcholine 200 mg (4cc) 16 cc NatriumChloride (NaCl) 0,9% in 20 cc syringe. (10 mg/ml)

Induction:

I: 1 ml/10 kg IBW II: 3 mg/ kg IBW or 3 ml/10 kg IBW III: 1 mg/kg TBW or 1ml /10 kg TBW

Maintenance:

I: 1 ml/10 kg IBW/ h. II: 0,5 tot 1 ml/ kg IBW/ h

Syringes or drugs used according to study group. Group A: 5 mg Remifentanyl in 50 cc (100 ug/ml). Bolus of 2 ug/kg IBW (0,2 ml / 10 kg IBW) followed by 10 - 50 ug/kg IBW/h (1 - 5 ml / 10 kg IBW / h) Group B: Sevoflurane inhalation 1 MAC in O2/air Group C: 200 mg rocuronium in 20 cc (10 mg/ml). Bolus of 1 ml / 10 kg IBW followed by 1 ml / 10 kg IBW/h

Anesthesia will be maintained with Propofol infusion at 5 - 10 mg/kg IBW/hour, lidocaine at 0,75 - 2,25 mg/kg IBW/h, Dexmedetomidine 0,5 - 1,4 ug/kg IBW/h and Ketamine 0,125 - 0,375 mg/kg IBW/h adapted according to Bispectral analysis (BIS) value ( keep below 60) and hemodynamic parameters (keep heart rate below 100 and SAP below 140mmHg).

Maximum infusion rate for propofol: 10 mg/kg/h; for lidocaine 3 mg/kg/h; for ketamine 0,5 mg/kg/h and for dexmedetomidine 1,4 mg/kg/h.

All patients will be ventilated with O2/air and a positive end expiratory pressure (PEEP) > 7 to an end tidal CO2 below 35 mmHg to prevent diaphragmatic activation.

A verres needle will be placed minimum 15 minutes after induction. If the surgeon is not able to place the verres needle in two attempts, every patient will be given a rocuronium bolus of 0.6 mg/kg IBW and the surgeon is asked after 5 minutes to repeat the trocar positioning. This will be noted as a failure to position the verres needle and to inflate the abdomen.

When the abdomen is inflated the first trocar is placed and the positions of the trocar and gastric tube verified, and the stomach confirmed to be empty.

The first abdominal pressure volume relation (APVR) will be measured using the following procedure by the surgeon:

  1. The abdomen is deflated of all air by manual palpation of the abdomen and turning the trocar. The abdomen is re-inflated successively to 0.5, 1, 1.5, and 2 liters (IAV), and, at each volume, the intra-abdominal pressure (IAP) is measured while inflation is stopped. A maximum pressure of 15 mmHg is used. The lowest IAP or end expiration value is taken. This allows the drawing of the first APVR, the calculation of the E, PV0, and inflated volume at 15 mmHg.
  2. At the end of insufflation, the insufflator is stopped and the insufflation line is closed with a clamp. The IAP is recorded while pressure stabilizes. If no stabilization is achieved in 15 seconds, a leak is possible and the patient is not included in the study or the step-wise inflation is repeated after the leak is closed.

Breathing against the ventilator or pressing is diagnosed when the IAP rises 5 mmHg above the set pressure not by a surgical act, when capnography shows irregularities in the waveform, or when the respiratory rate is higher than the set value. These patients are not included in the randomisation.

All remaining patients will be randomly assigned to three groups. A randomization number will be generated by the secretary of anesthesia at the moment of the patient's enrollment, using a random number generator. The anesthesiologist will be informed of the number when ready to prepare the drugs available from the pharmacy.

The anesthesiologist will not be blinded (i.e., he/she will know what drug he/she gives), because the administration routes are different: iv infusion, iv bolus, or inhalation. The surgeon and OR nurses will be blinded to the drugs used as iv infusion and bolus will always be given.

Group A: A bolus of remifentanyl 2 µg/kg IBW (0,2 ml/ 10 kg IBW) will be given and followed by 10 - 50 ug/kg IBW/h remifentanyl infusion (1 - 5 ml / 10 kg IBW / h). The propofol and dexmedetomidine infusion will be continued but adapted in dose when needed after the measurements.

Group B: Desflurane inhalation at 1 MAC N2/O2 will be started with a fresh gas flush of the ventilator ( using et tidal control function) until the end tidal concentration reaches 1 MAC while the propofol infusion is stopped. The Ketamine Lidocaine Dexmedetomidine infusion is continued.

Group C: A bolus dose of rocuronium 1 mg/kg IBW will be given while the propofol and Dexmedetomidine infusion is continued.

After the above drugs are administered, there will be a waiting period of 5 minutes while the abdomen remains deflated in all groups. The BIS value should stay below 40% in all groups until the second APVR is measured, using the same setup as the first measurement.

After the second APVR measurement the pressure needed to reach 4 liter is calculated and the insufflator is set to this value with a maximum of 15 mmHg in every patient. If during the second APVR the patient presses or breathes against the ventilator this will be noted as a failure to measure the APVR. A dose of rocuronium 1 mg/kg IBW is given followed by an infusion to keep PTC < 4.

The anesthesia is continued with propofol/remifentanyl/Dex in group A, with sevoflurane/Dex in group B, and with Propofol/Dex/Rocuronium in group C. A bolus of sufentanil can be added in any patient after the two APVR measurements, at the discretion of the anesthesiologist.

The surgeon is asked 5 minutes after second APVR if he has sufficient workspace to reach all places he need to operate. He is asked to grade this on a scale of 1 to 5, with 5 excellent and 1 impossible. If the grade is less than 3 and patient didn't get yet any NMB until that time a bolus of rocuronium 1 mg/kg IBW is given. The NMB will be kept in these patients at train of four (TOF) = 0 and PTC < 4 until release of the pneumoperitoneum.

A reversal with 4 mg/kg sugammadex will be given before awakening the patient. Any inadvertent event will be noted. TOF monitoring will be used in all patients to verify when and how deep NMB is given and to verify that sugammadex returns the TOF to a minimum of 90%.

An external statistical group revealed that an enrollment of 12, 14 and 16 patients in the first, second and third group would be sufficient. The difference between the three groups is due to the fact that a comparison is needed between NMB and the other drugs, not between remifentanyl and sevoflurane.

A two way Anova will be used to evaluate the different effect of remifentanyl, sevoflurane versus rocuronium on the abdominal workspace (pressure needed to achieve 4 l) and on the surgical incidence of having an insufficient workspace. ( 2 independent variables, three conditions)

Being tested
rocuronium, Sevoflurane, remifentanyl
Keywords
pneumoperitoneum, laparoscopy
Medical subject headings
Pneumoperitoneum

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • rocuroniumDrug

    Also called esmeron

    measure effect on laparoscopic workspace

  • SevofluraneDrug

    Also called sevorane

    1 MAC sevoflurane inhalation is given

  • remifentanylDrug

    Also called ultiva

    remifentanyl is given in infusion

Study groups in NCT01930747
Study groupRoleWhat they receive
deep neuromuscular blockExperimentaldeep neuromuscular block is given after first measurement of lap workspace one bolus dose of 1 mg/kg rocuronium is given
Receives: Drug: rocuronium
inhalation with 1 MAC SevofluraneExperimental1 MAC Sevoflurane inhalation is given after first measurement of lap workspace
Receives: Drug: Sevoflurane
remifentanylExperimentalremifentanyl infusion is given after first measurement of lap workspace
Receives: Drug: remifentanyl

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effect of Anesthetics on the Pressure at Zero Volume (PV0) Measured During Insufflation of the Abdomen

    the impact of the following agents on the pressure at zero volume (PV0): remifentanyl > 0.50 µg/kg/min; sevoflurane 1 MAC and deep neuromuscular block (rocuronium given with PTC < 4).

    Measured: 5 min after reaching 1 MAC or haven given the anesthetics intravenous

  2. Effect of Anesthetics on the Abdominal Elastance (E) Measured During Insufflation of the Abdomen by

    the impact of the following agents on the abdominal elastance (E) : remifentanyl > 0.50 µg/kg/min; sevoflurane 1 MAC and deep neuromuscular block (rocuronium given with PTC < 4).

    Measured: 5 min after reaching 1 MAC or haven given the anesthetics intravenous

Secondary outcomes (1)
  1. Adverse Events Difference Between the Three Groups

    To compare the major adverse events among the patient groups who receive the different agents listed above in the "primary efficacy objective"

    Measured: from zero till 24 hours after recovery of surgery.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Aug 2013 (estimated)
  2. Study startApr 2013
  3. Primary completionDec 2015
  4. Study completionApr 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01930747
Sponsor's protocol ID
2013JPM2
Acronym
TIVA
Status last verified
May 2019
First submitted
30 May 2013
Last updated
29 May 2019
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing rocuronium, Sevoflurane and remifentanyl in people with Muscle Relaxation, run by AZ Sint-Jan AV at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 May 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effect of Anesthetics on the Pressure at Zero Volume (PV0) Measured During Insufflation of the Abdomen (time frame: 5 min after reaching 1 MAC or haven given the anesthetics intravenous). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in